β-HCG、CEA、CA125联检在宫颈癌病情进展中的临床研究与安全性评价  

The Clinical Significance of Combination of Determination of CEA,CA125 and β-HCG in Cervical Carcinoma Progression

作　　者：郝小云 HAO Xiao- yun(Hanyuan People＇s Hospital of Sichnan Province, Ya＇an 625300, Chin)

机构地区：[1]四川省汉源县人民医院检验科,四川雅安625300

出　　处：《标记免疫分析与临床》2018年第5期673-675,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：目的分析血清肿瘤标志物癌胚抗原(CEA)、糖类抗原125(CA125)以及人绒毛膜促性腺激素(β-HCG)联合检测在宫颈癌病情进展中的临床价值与安全性。方法选取2007年7月至2017年7月我院收治的276例宫颈癌患者为研究对象,并纳入观察组,以同期入院体检的宫颈良性病变患者266例为对照组,测定两组血清CEA、CA125、β-HCG水平,分析CEA、CA125、β-HCG联检与单独检测诊断宫颈癌的灵敏度、准确度、特异性、阳性检出率之间的差异,并分析差异是否有统计学意义。结果宫颈癌组血清CEA、CA125、β-HCG水平明显高于对照组,差异有统计学意义(P<0.05);CEA、CA125、β-HCG联合检测诊断宫颈癌的灵敏度84.78%、准确度71.74%、特异性76.09%、阳性检出率82.61%,均高于上述指标单项(P<0.05)。结论血清肿瘤标志物癌胚抗原(CEA)、糖类抗原125(CA125)以及人绒毛膜促性腺激素(β-HCG)联合检测在宫颈癌病情进展中具有重要的临床价值,且明显高于单项检测的临床价值,值得临床推广。Objective To analyze the significance of the determination of carcinoembryonic antigen （CEA）, carbohydrate antigen 125 （CA 125)and human chorionic gonadotropin （β-HCG）combination in the progression of cervical carcinoma. Methods A total of 276 cases of cervical carcinoma patients were enrolled as test group, along with 266 cases of benign cervical lesions patients as control group from July 2007 to July 2017. And among all of the patients, we measured the levels of the tumor biomarker CEA, CA 125 and β-HCG in serum. Then the sensitivity, accuracy, specificity and positive rate were calculated and used for comparison of the combination detection and solo detection. Results The levels of CEA, CA 125 and 13-HCG were found higher in the test group compared with the control group (P 〈 0.05). And the sensitivity, accuracy,specificity and positive rate of combination detection for cervical carcinoma were 84. 78%, 71.74% ,76.09% and 82.61% ,respectively, which were significantly higher than that of the solo detection. Conclusion The combination detection of serum tumor biomarkers （CEA, CA125 and β-HCG）in cervical carcinoma progression was shown in great clinical significance and should be promoted.

关 键 词：肿瘤标记物 宫颈癌 CEA CA125 Β-HCG 

分 类 号：R730.43[医药卫生—肿瘤] R737.33[医药卫生—临床医学]